SCOPE-1
Regimen
- Experimental
- cisplatin/capecitabine + 50 Gy RT + cetuximab
- Control
- cisplatin/capecitabine + 50 Gy RT (definitive CRT)
Population
Esophageal cancer (~73% squamous) treated with definitive chemoradiotherapy
Key finding
Median OS 34.5 mo (dCRT) vs 24.7 mo (dCRT+cetuximab), HR 1.25 (NS); cetuximab arm worse. Importantly, dCRT-alone arm's mOS 34.5 mo is a UK-contemporary benchmark for the CapOx + 50Gy definitive CRT regimen.
Source: PMID 28196063